ASCO 2023 – China’s Dizal claims broad coverage with a super-Tagrisso
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
ASCO 2023 – Servier’s Indigo win comes with liver tox
Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.
ASCO 2023 – Bristol’s Commands data look good for Geron
The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.
